Skip to main content

Table 1 NeoALTTO patient characteristics by body mass index (BMI) categories

From: Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

 

Overall (N = 454)

BMI categories

 

Underweight (N = 14)

Normal weight (N = 220)

Overweight (N = 137)

Obese (N = 83)

p value

Median age (years) at baseline

50

46

48

51

52

< 0.001

Randomized arm, N (%)

 L

153 (34)

1 (7)

83 (38)

49 (36)

20 (24)

0.099

 T

149 (33)

6 (43)

71 (32)

40 (29)

32 (39)

 

 L + T

152 (33)

7 (50)

66 (30)

48 (35)

31 (37)

 

Clinical tumor size, N (%)

 ≤ 5 cm

274 (60)

9 (64)

135 (61)

79 (58)

51 (61)

0.887

 > 5 cm

180 (40)

5 (36)

85 (39)

58 (42)

32 (39)

 

HR status, N (%)

 Negative

223 (49)

3 (21)

110 (50)

73 (53)

37 (45)

0.112

 Positive

231 (51)

11 (79)

110 (50)

64 (47)

46 (55)

 

Menopausal status, N (%)

 Post-menopausal

189 (42)

5 (36)

76 (35)

68 (50)

40 (48)

0.036

 Pre-menopausal

219 (48)

9 (64)

122 (55)

53 (39)

35 (42)

 

 NA and age < 50

14 (3)

0

9 (4)

2 (1)

3 (4)

 

 NA and age ≥ 50

32 (7)

0

13 (6)

14 (10)

5 (6)

 

Histology grade, N (%)

 G1

12 (3)

1 (7)

2 (< 1)

5 (4)

4 (5)

0.121

 G2

171 (38)

8 (57)

91 (41)

48 (35)

24 (29)

 

 G3

205 (45)

3 (21)

101 (46)

62 (46)

39 (47)

 

 GX

65 (14)

2 (14)

26 (12)

21 (15)

16 (19)

 

Planned surgery, N (%)

 Conservative surgery

130 (29)

5 (36)

63 (29)

39 (28)

23 (28)

0.944

 Mastectomy

324 (71)

9 (64)

157 (71)

98 (72)

60 (72)

 

Clinical nodal status, N (%)

 N0/1

382 (84)

13 (93)

189 (86)

112 (82)

68 (82)

0.531

 ≥ N2, Nx or missing

72 (16)

1 (7)

31 (14)

25 (18)

15 (18)

 
  1. HR hormone receptor, BMI body mass index, L lapatinib, T trastuzumab, L+T lapatinib + trastuzumab, NA non-available